profit from every $100 of sales.
$0$100
Universe Pharmaceuticals
$1.51-1.31% today
-79.8% in 1 year
1-year low $1.391-year high $11.24
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Universe Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $40.1 million in 2022 to $17.9 million in 2025, with -$3.67 million of profit last year.
SalesProfit
Universe Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Universe Pharmaceuticals | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Universe Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 40 | 32 | 23 | 18 | |
| 22 | 10 | 6 | 6 | |
| -7 | -4 | -8 | -3 | |
| -6 | -4 | -7 | -3 | |
| -8 | -7 | -9 | -4 | |
| -1,335.29 | -1,089.21 | -626.96 | – | |
| 54.5% | 31.9% | 26.4% | 35.3% | |
| -17.5% | -12.3% | -34.8% | -16.3% | |
| -19.7% | -20.4% | -37.9% | -20.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 60 | 42 | 68 | 69 |
| Cash | 6 | 5 | 29 | 34 |
| Total debt | 4 | 5 | 8 | 9 |
| Total liabilities | 13 | 14 | 22 | 13 |
| 46 | 28 | 46 | 56 | |
| 0 | 0 | 0 | – | |
| -10.9% | -9.8% | -11.6% | -4.2% | |
| -17.0% | -23.5% | -19.2% | -6.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | 1 | -10 | -5 | |
| 0 | 0 | 0 | 0 | |
| -1 | 1 | -10 | -5 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 0.0×
- 0.4×
- –
- –
- -71.2%
- -48.4%
- 0.0%
Profitability
- 35.3%
- -16.3%
- -20.6%
- -16.4%
- -4.5%
- -7.0%
- -6.6%
- -5.3%
- -5.2%
- 3.8%
Growth
- −23.7%
- –
- +45.3%
- –
- −9.9%
Financial health
- -8.3×
- 0.16
- 13.4%
- -12.6×
- 4.07
- 3.90
- 0.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 963
Bottom 12%of 894
Bottom 4%of 908
Bottom 1%of 991
News
Why SpaceX’s stock is surging — and lifting the broader AI universe along with itMarketWatch · Oct 21, 2026YieldMax® Universe Fund of Option Income ETFs declares $0.0598 dividendSeeking Alpha · Sep 8, 2026SpaceX launches NASA's $4.3B Roman telescope to probe dark universeSeeking Alpha · Aug 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
72Pass
Philip Fisher
43No pass
Peter Lynch
27No pass
Joel Greenblatt
0No pass
Charlie Munger
43No pass
Terry Smith
40No pass
Questions about Universe Pharmaceuticals
Is Universe Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Universe Pharmaceuticals AI analysis
What does Universe Pharmaceuticals do?
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It is in Drug Manufacturers - Specialty & Generic.
Does Universe Pharmaceuticals pay a dividend?
No. Universe Pharmaceuticals does not pay a dividend at the moment.
Is Universe Pharmaceuticals stock halal?
No. Universe Pharmaceuticals does not pass our halal screen: its debt is 122% of its market value, at or above the 33% limit. How we check
How has Universe Pharmaceuticals stock done over the past year?
Down 79.8% over the past twelve months, to $1.51. It traded between $1.39 and $11.24 and is 86.6% below its high.
Who are Universe Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Universe Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.